EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Pharmacokinetics of beta-L-2',3'-dideoxy-5-fluorocytidine in rhesus monkeys



Pharmacokinetics of beta-L-2',3'-dideoxy-5-fluorocytidine in rhesus monkeys



Antimicrobial Agents and ChemoTherapy 43(4): 920-924



beta-L-2',3'-Dideoxy-5-fluorocytidine (beta-L-FddC), a novel cytidine analog with an unnatural beta-L sugar configuration, has been demonstrated by our group and others to exhibit highly selective in vitro activity against human immunodeficiency virus types 1 and 2 and hepatitis B virus. This encouraging in vitro antiviral activity prompted us to assess its pharmacokinetics in rhesus monkeys. Three monkeys were administered an intravenous dose of [3H] beta-L-FddC at 5 mg/kg of body weight. Following a 3-month washout period, an equivalent oral dose was administered. Plasma and urine samples were collected at various times for up to 24 h after dosing, and drug levels were quantitated by high-pressure liquid chromatography. Pharmacokinetic parameters were obtained on the basis of a two-compartment open model with a first-order elimination from the central compartment. After intravenous administration, the mean peak concentration in plasma (Cmax) was 29.8 +/- 10.5 microM. Total clearance, steady-state volume of distribution, terminal-phase plasma half-life (t1/2 beta), and mean residence time were 0.7 +/- 0.1 liters/h/kg, 1.3 +/- 0.1 liters/kg, 1.8 +/- 0.2 h, and 1.9 +/- 0.2 h, respectively. Approximately 47% +/- 16% of the intravenously administered radioactivity was recovered in the urine as the unchanged drug with no apparent metabolites. beta-L-FddC exhibited a Cmax of 3.2 microM after oral administration, with a time to peak drug concentration of approximately 1.5 h and a t1/2 of 2.2 h. One monkey in the oral administration arm of the study had a significant delay in the absorption of the aqueous administered dose. The absolute bioavailability of orally administered beta-L-FddC ranged from 56 to 66%.

(PDF emailed within 1 workday: $29.90)

Accession: 011137446

Download citation: RISBibTeXText

PMID: 10103200



Related references

Pharmacokinetics of beta-D-2,3-didehydro-2,3-dideoxy-5-fluorocytidine in rhesus monkeys. Antiviral Research 37(3): A47, March, 1998

Pharmacokinetics of the antiviral agent beta-D-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine in rhesus monkeys. Antimicrobial Agents and ChemoTherapy 43(2): 381-384, 1999

Pharmacology and pharmacokinetics of the antiviral agent beta-D-2',3'-dideoxy-3'-oxa-5-fluorocytidine in cells and rhesus monkeys. Antimicrobial Agents and ChemoTherapy 49(7): 2589-2597, 2005

Studies of the pharmacokinetics and toxicology of 2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC) and 2',3'-dideoxy-beta-L-cytidine (beta-L-ddC) in vivo; and synthesis and antiviral evaluations of 2',3'-dideoxy-beta-L-5-azacytidine. Nucleosides and Nucleotides 14(3-5): 619-625, 1995

Studies of the pharmacokinetics and toxicology of 2,3-dideoxy-beta-L-5-fluorocytidine and 2,3-dideoxy-beta-L-cytidine in vivo; and synthesis and antiviral evaluations of 2,3-dideoxy-beta-L-5-azacytidine. Nucleosides & Nucleotides 14(3-5): 619-625, 1995

Pre-clinical pharmacology of beta-L-2,3-dideoxy-5-fluorocytidine and its prodrug bis- SATE-beta-L-2,3-dideoxy-5-fluorocytidine monophosphate. Antiviral Research 37(3): A64, March, 1998

Preclinical pharmacokinetics of beta-D-2,3-didehydro-2,3-dideoxy-5-fluorocytidine in woodchucks. Pharmaceutical Research (New York) 14(11 SUPPL ): S73, 1997

In vitro and in vivo metabolism and pharmacokinetics of bis -S-acyl-2-thioethyl-beta-2,3-dideoxy-5-fluorocytidine monophosphate. Nucleosides Nucleotides & Nucleic Acids 19(1-2): 481-499, 2000

In vitro and in vivo metabolism and pharmacokinetics of bis [(t-butyl)-S-acyl-2-thioethyl]-beta-L-2',3'-dideoxy-5-fluorocytidine monophosphate. Nucleosides, Nucleotides & Nucleic Acids 19(1-2): 481-499, 2000

In vitro and in vivo metabolism and pharmacokinetics of bis ((T-butyl)-S-acyl-2-thioethyl)-beta-2',3'-dideoxy-5-fluorocytidine monophosphate. Nucleosides Nucleotides and Nucleic Acids 19(1-2): 481-499, 2000

Antiviral activity of 2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC) and 2',3'-dideoxy-beta-L-cytidine (beta-L-ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro. Biochemical Pharmacology 47(2): 171-174, 1994

Immunomodulatory and antiviral activities of 2',3'-dideoxy-beta-L-cytidine and 2',3'-dideoxy-beta-L-5-fluorocytidine. Immunopharmacology and Immunotoxicology 17(1): 17-32, 1995

Pharmacokinetics of -2,3-dideoxy-5-fluoro-3-thiacytidine and its metabolites in rhesus monkeys. Antiviral Research 34(2): A68, 1997